Literature DB >> 8492743

Characterization of the mouse type X collagen gene.

S S Apte1, B R Olsen.   

Abstract

Type X collagen, a homotrimer of alpha 1 (X) polypeptide chains, is specifically expressed by hypertrophic chondrocytes in regions of cartilage undergoing endochondral ossification. We have previously characterized a genomic clone containing the major part of the mouse type X collagen gene (col10a1) and assigned the locus for col10a1 to mouse chromosome 10 (Apte et al., Eur. J. Biochem. 224: 217-224, 1992). In this paper, through additional characterization of cDNA and genomic clones, we describe the complete organization of the col10a1 gene. The col10a1 gene is 7.2 kb in size and, as in the chick, col10a1 gene transcripts are generated from only three exons. Exon 1 encodes only the 5' untranslated (5' UT) region of the mRNA and is separated from exon 2 by an intron 562 bp in length. Exon 2 (169 bp) encodes 15 bp of 5' UT message, the translation start plus 17-amino acid residues of the putative signal peptide, and 33 1/3 codons of the putative N-terminal non-collagenous (NC2) domain of type X collagen. Exon 3 is 2854 bp in size and encodes 4 2/3 codons of the NC2 domain, the entire collagenous domain of 463 residues (COL), the entire C-terminal non-collagenous (NC1) domain (161 amino acid residues) and the entire 965 bp 3' untranslated (3' UT) sequence of the mRNA. Two TATA boxes are present in tandem in the col10a1 promotor. Both TATA boxes are active in transcription, generating two populations of transcripts with different 5'-termini; the longer transcript is of low abundance and is detectable only by PCR in newborn mice. The col10a1 promotor contains a CCAAT box as well as other consensus sequence elements required for binding of potential transcription factors. Characterization of the col10a1 gene provides data essential for studies of the regulation of type X collagen expression during mammalian endochondral bone growth and development. Knowledge of the complete structure of the mouse type X collagen gene will also be useful for the investigation of type X collagen gene abnormalities in murine chondrodysplasias and for the generation of transgenic mice.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8492743     DOI: 10.1016/s0934-8832(11)80075-2

Source DB:  PubMed          Journal:  Matrix        ISSN: 0934-8832


  6 in total

1.  In situ hybridisation study of type I, II, X collagens and aggrecan mRNas in the developing condylar cartilage of fetal mouse mandible.

Authors:  K Fukada; S Shibata; S Suzuki; K Ohya; T Kuroda
Journal:  J Anat       Date:  1999-10       Impact factor: 2.610

2.  A dominant interference collagen X mutation disrupts hypertrophic chondrocyte pericellular matrix and glycosaminoglycan and proteoglycan distribution in transgenic mice.

Authors:  O Jacenko; D Chan; A Franklin; S Ito; C B Underhill; J F Bateman; M R Campbell
Journal:  Am J Pathol       Date:  2001-12       Impact factor: 4.307

3.  A nonsense mutation in the carboxyl-terminal domain of type X collagen causes haploinsufficiency in schmid metaphyseal chondrodysplasia.

Authors:  D Chan; Y M Weng; H K Graham; D O Sillence; J F Bateman
Journal:  J Clin Invest       Date:  1998-04-01       Impact factor: 14.808

4.  Mutations in three subdomains of the carboxy-terminal region of collagen type X account for most of the Schmid metaphyseal dysplasias.

Authors:  J Bonaventure; F Chaminade; P Maroteaux
Journal:  Hum Genet       Date:  1995-07       Impact factor: 4.132

5.  Transcriptional profiling of chondrodysplasia growth plate cartilage reveals adaptive ER-stress networks that allow survival but disrupt hypertrophy.

Authors:  Trevor L Cameron; Katrina M Bell; Liliana Tatarczuch; Eleanor J Mackie; M Helen Rajpar; Ben T McDermott; Raymond P Boot-Handford; John F Bateman
Journal:  PLoS One       Date:  2011-09-15       Impact factor: 3.240

6.  Expression profiling of Dexamethasone-treated primary chondrocytes identifies targets of glucocorticoid signalling in endochondral bone development.

Authors:  Claudine G James; Veronica Ulici; Jan Tuckermann; T Michael Underhill; Frank Beier
Journal:  BMC Genomics       Date:  2007-07-01       Impact factor: 3.969

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.